NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

368.40 14.05 (3.97%)

High volume today

NSE 18 Sep, 2025 3:31 PM (IST)

49,253.7

Market Cap

Market Leader

1.2

Beta 1Year

Very High Volatility

US FDA Approval

Biocon's arm gets US FDA approval for Bosaya and Aukelso injections with a market size of $5 bn See details

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Search Inside the pdf :

Biocon Ltd.

11 Aug 2025

368.40

3.97%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 380/share, implying an 11% upside potential from the CMP.

Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 qtr

Biocon Ltd.

09 Aug 2025

368.40

3.97%

Margin pressure persists

Sell: Biocon Ltd.

Target

ICICI Securities Limited

Biocon’s Q1FY26 performance was marred by operating cost of new facilities for generic division and lower-thananticipated margins in biologics division.

Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 qtr

Biocon Ltd.

08 Aug 2025

368.40

3.97%

Temporary headwinds in generics weigh on 1Q

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) reported lower-than-expected financial performance in 1QFY26, affected mainly by a sharp reduction in generics sales and increased opex related to new facilities.

Number of FII/FPI investors increased from 305 to 333 in Jun 2025 qtr.

Biocon Ltd.

03 May 2025

368.40

3.97%

Pick of the Week:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We recommend BUY with TP of Rs 351, which implies an upside of 10% from the current market price (CMP).

Biocon Ltd.'s price crossed above 100Day SMA today

Biocon Ltd.

01 Feb 2025

368.40

3.97%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 405/share, implying a 12% upside potential from CMP

Biocon Ltd. is trading above its 200 day SMA of 354.1

Biocon Ltd.

13 Jan 2025

368.40

3.97%

‘VAI’ status for Malaysian site provides regulatory boost

Buy: Biocon Ltd.

Recommendation Target

Motilal Oswal

Biocon (BIOS) has received ‘Voluntary Action Indicated’ (VAI) status for its Malaysian site. With this, BIOS now has all critical sites for biosimilars under USFDA compliance, improving its business prospects in the US market.

Number of FII/FPI investors increased from 305 to 333 in Jun 2025 qtr.

Biocon Ltd.

20 Nov 2024

368.40

3.97%

BIOCON LTD

Accumulate: Biocon Ltd.

Target

Geojit BNP Paribas

Biocon Ltd.'s price crossed above 100Day SMA today

Biocon Ltd.

12 Nov 2024

368.40

3.97%

Soft quarter, expect recovery in H2

Buy: Biocon Ltd.

Sharekhan

Revenues stood at Rs. 3,590 crore, up 4% y-o-y and a 5% rise q-o-q. EBITDA reached Rs. 730 crore, down 1% y-o-y but up 24% q-o-q. PAT stood at Rs. 27 crore, a decline of 84% y-o-y and 97% q-o-q.